The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases.

• Interleukin-17 is a proinflammatory cytokine involved in chronic inflammation. • Interleukin-17 is involved in the pathogenesis of various immune-mediated diseases. • Several IL-17 and IL-17R inhibitors were approved to treat some immune-mediated diseases. • Ixekizumab, Secukinumab, and Brodalumab monoclonal antibodies target IL-17A and IL-17R. • Ixekizumab, Secukinumab, and Brodalumab are extremely effective to treat Psoriasis. Interleukin-17 (IL-17) is a proinflammatory cytokine involved in chronic inflammation occurring during the pathogenesis of allergy, malignancy, and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and psoriasis. IL-17 is produced by multiple cell types of adaptive and innate immunity, including T helper 17 cells, CD8 + T cells, γδ T cells, natural killer T cells, and innate lymphoid cells. Monoclonal antibodies (mAbs) targeting IL-17 and/or IL-17R would be a potential approach to study this therapeutic tool for these diseases. In the current review, we aimed to highlight the characteristics of IL-17 and its important role in the pathogenesis of related diseases. Critical evaluation of the mAbs targeting IL-17A and IL-17 receptors (e.g., Ixekizumab, Secukinumab, and Brodalumab) in various immune-mediated diseases will be provided, and finally, their clinical efficacy and safety will be reported. [ABSTRACT FROM AUTHOR]